Hypertension is one of the most common human diseases worldwide, and extensive research efforts are focused upon the identification and utilizing of novel therapeutic drug targets. Nitric oxide (NO) produced by endothelial NO synthase (eNOS) is an important regulator of blood pressure (BP). b-Lapachone (bL), a well-known substrate of NAD(P)H:quinone oxidoreductase (NQO1), increases the cellular NAD + /NADH ratio via the activation of NQO1. In this study, we evaluated whether bL-induced activation of NQO1 modulates BP in an animal model of hypertension.
Introduction
Uncontrolled hypertension is a key risk factor for cerebrovascular accidents, myocardial infarction, cardiac failure, arterial aneurysm, and chronic renal failure. 1 Although many anti-hypertensive medications have been developed and extensive research efforts focus on the exploitation of novel therapeutic drug targets, the percentage of hypertensive patients with blood pressures (BPs) in the control range (usually ,140/90 mmHg) remains low. 1 -4 Nitric oxide (NO), an endothelium-derived relaxing factor, 5 is an important regulator of vascular tone and BP and is synthesized by endothelial NO synthase (eNOS). 6 Blocking eNOS with pharmacological inhibitors causes significant peripheral vasoconstriction and elevation of BP. 7 The major determinants of NO synthesis by eNOS include phosphorylation and intracellular concentration of free Ca 2+ ([Ca 2+ ]i). 8 -10 In endothelial cells, phosphorylation of the eNOS carboxy-terminus at serine 1177 (Ser 1177 ) is crucial to eNOS activation. 11, 12 Protein kinase B/ Akt is the major kinase for eNOS phosphorylation at Ser 1177 , 11 and AMP-activated protein kinase (AMPK) also plays an important role in regulating eNOS protein expression. 13 In endothelial cells, store- 19 and significantly reduced NAD + / NADH ratios were observed in the liver and kidneys of NQO1
-/ -mice. 20 Several activators and substrates of NQO1 have been identified. One well-known NQO1 substrate is b-lapachone (bL; 3,4-dihydro-2,2-dimethyl-2H-naphtho [1,2-b] pyran-5,6-dione). 21, 22 bL extract, isolated from the bark of the Lapacho tree, has been used as a folk medicine for centuries 23 and initial studies have demonstrated its ability to inhibit tumour growth. 24 Recent studies have indicated that bL increases the NAD + /NADH ratio via NQO1 activation. Moreover, an increased cytoplasmic NAD + /NADH ratio has beneficial effects on several features of metabolic syndrome, including obesity amelioration in mice and prevention of arterial smooth muscle cell proliferation in rats. 25, 26 In this study, we observed that the increased NAD + /NADH ratio resulting from NQO1 activation lowered BP via aortic endothelial eNOS modulation in spontaneously hypertensive rats (SHR). Here, we have introduced the experimental results and the underlying mechanism.
Methods

Materials
bL was chemically synthesized by Mazence Co (Suwon, Korea). v-Nitro-L-arginine methyl ester (L-NAME), acetylcholine, phenylephrine, 1,2-Bis(2-aminophenoxy)ethane-N,N,N ′ ,N ′ -tetraacetic acid tetrakis (BABTA-AM), ethylene glycol tetraacetic acid (EGTA), 8-Br-cADPR, ES936, nicotinamide, LY249002, Wortmannin, compound C and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) were purchased from Sigma Chemical Co (St Louis, MO, USA). Dicoumarol was purchased from Calbiochem (San Diego, CA, USA). Anti-eNOS antibody was purchased from BD Biosciences (San Diego, CA, USA). Anti-phospho-eNOS-Ser 1177 , Anti-phospho-eNOS-Thr 495 , anti-phosphoAkt-Ser 473 , anti-phospho-Akt, anti-phospho-AMPK-Thr 172 , anti-AMPK, anti-phospho-ACC-Ser 79 , and anti-ACC antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-NQO1 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Animals and experimental procedures
Twelve-week-old male SHR were purchased from an established colony at the Japan SLC (Inasa Production Facility, Japan). Experimental animals were assigned to three groups: (i) Group 1 included two subgroups that received either a regular chow diet or a diet containing bL (Mazence Co., Korea; 0.12%, wt/wt) for 3 days; (ii) Group 2 included two subgroups that received either a regular chow diet or a diet containing bL for 4 weeks; and (iii) Group 3 comprised three subgroups, a control group that received a regular chow diet for 6 weeks, a bL group that received bL in the diet for 6 weeks, and a bL + L-NAME group that received the same diet with bL group for the first 3 weeks followed by the addition of eNOS inhibitor L-NAME to drinking water for 7 days during Week 4 and 6 (50 mg/kg/day 
Cell culture
Primary human aortic endothelial cells (HAEC) and mouse brain endothelial (bEnd.3) cells were purchased from ATCC. HAEC were cultured in endothelial basal medium-2 (EBM-2) medium supplemented with EGM-2 bullet kits (Endothelial Growth Medium-2; Lonza, Basel, Switzerland). bEnd.3 cells were maintained in DMEM (Dulbecco's modified Eagle's medium; Hyclone Laboratory, UT, USA) supplemented with 10% foetal bovine serum, 0.5% bovine serum albumin, 250 mmol/L dimethyl sulfoxide, 100 U/mL penicillin, and 100 mg/mL streptomycin in a humidified atmosphere (5% CO 2 /95% air) at 378C.
Measurement of BP
Systolic BP (SBP) and diastolic BP (DBP) were measured in all animals each week following treatment. The rats were preheated to dilate their tail vessels first for 15 -20 min at 398C in a warming box and then BP was measured using the non-invasive tail cuff method in a restrainer heated electrically to 398C. The animals were pre-trained with the apparatus (Softron BP-98A, Tokyo, Japan) at least three times before measurements, and BP was determined.
Measurement of cellular total NAD
1
/NADH ratio
Cells were harvested with 80% methanol and lysed mechanically using a 31-gauge needle. Electrospray ionization mass spectrometry was performed in positive ion mode as described previously (see Supplementary materials online, Methods). 
Organ-bath study for vascular reactivity
We used 12-week-old male SHR that had received either a regular chow diet or bL in the diet (0.12% wt/wt) for 4 weeks. The animals were anaesthetized (50 mg/kg sodium pentobarbital, ip), and the adequacy and the depth of anaesthesia condition was monitored based on paw-pinch test. After then, the thoracic aorta was immediately excised and immersed in an ice-cold modified Krebs solution. The aorta was cleansed of all adherent connective tissue using wet filter paper soaked in Krebs bicarbonate solution, and cut into four ring segments (4 mm in length) as described in a previous study. 29 The rings were not denuded of endothelium, and two stainless steel triangles were inserted through each vessel ring. Each aortic ring was suspended in a water-jacketed organ bath (22 mL), maintained at 378C, and aerated with a mixture of 95% O 2 /5% CO 2 .
One triangle was anchored to a stationary support, and the other was connected to an isometric force transducer (Grass FT03C; Grass Instruments, Quincy, MA, USA). The rings were stretched passively by imposing the optimal resting tension, 2.0 g, which was then maintained throughout the experiment. Each ring was equilibrated in an organ-bath solution for 90 min. The viability and endothelial integrity of the aortic ring were confirmed with the contractile response to 10 26 mol/L phenylephrine and 10 27 mol/L acetylcholine. Isometric contractions were recorded using a computerized data acquisition system (PowerLab/8SP; AD Instruments Pty. Ltd., Castle Hill, Australia). For the measurement of contractile response, aortic rings were pre-treated with 10 26 mol/L phenylephrine and subjected to the cumulative addition of acetylcholine (10 29 -10 25 mol/L). Endothelium-dependent vasodilation was determined by generating dose-response curves for acetylcholine. Vasorelaxation in response to acetylcholine was expressed as a percentage contraction, determined by the percentage of inhibition to the pre-constriction tension. Endothelium-dependent NOS-independent vasorelaxation was assessed by generating dose-response curves to acetylcholine in rings pre-treated with the NOS inhibitor L-NAME (10 24 mol/L).
Endothelium-independent vasodilation was measured by vasorelaxation in response to cumulative sodium nitroprusside in rings pre-constricted with phenylephrine (10 26 mol/L).
Measurement of eNOS activity
The L-NAME was added to drinking water for 7 days during Week 4 and 6 (50 mg/kg/day) in the bL + L-NAME group. (B and C) BP was measured six times using the tail cuff method. SBP and DBP measurements were analysed on the basis of the resting SBP. The SBP (B) and DBP (C) were evaluated using the mean value of six measurements under stable-heart rate conditions. Control group, n ¼ 5; bL group, n ¼ 6; bL + L-NAME group, n ¼ 6; grouped quantitative data are presented as means + SEM. ANOVA, *P , 0.05, **P , 0.01, bL group compared with control group; ## P , 0.01, bL + L-NAME group compared with control group. The cellular NAD + /NADH ratio was analysed in bEnd.3 cells. (D) Cells were treated with 10 mmol/L bL for 15 min. Treated cells were harvested with 80% methanol, and the supernatant was used for NAD + and NADH measurements. The NAD + /NADH ratio was calculated from levels of total NAD + and total NADH measured by high performance liquid chromatography/mass spectrometry/mass spectrometry analysis. (E) Cells were treated with 10 mmol/L bL for 15 min. Treated cells were harvested with 1 mol/L perchloric acid. The supernatant was used for pyruvate and lactate measurements. Grouped quantitative data are presented as means + SEM from a minimum of three independent experiments. Student's t-test, *P , 0.05, and **P , 0.01 compared with the control group.
Silencing of NQO1
At 30% confluence, bEnd.3 cells were transfected with HyperFect transfection reagent (Qiagen, Hilden, Germany) containing scrambled control siRNA (Invitrogen) or Nqo1-specific siRNA (AAACCAGCCUUU CAGAAUGGCUGGC; Invitrogen) following the manufacturer's instructions.
Adenoviral infection
Adenovirus encoding dnAMPKa was kindly provided by Dr In-Kyu Lee (Kyungpook National University School of Medicine), 26 and bEnd.3 cells were infected with adenoviral vectors.
Western blot analysis
Protein abundances and phosphorylation in isolated protein were analysed using western blot according to standard procedures (see Supplementary materials online, Methods).
Immunofluorescence staining
Paraffin sections were used for immunofluorescence staining. Following deparaffinizing and rehydration, the sections were treated with sodium citrate buffer (pH 6.5) and microwaved for 15 min. The sections were cooled for 30 min at room temperature and then incubated with 3% bovine serum albumin for 1 h. The tissue sections were incubated overnight at 48C with anti-eNOS antibody (1:200). Alexa Fluoro 546 nm anti-mouse antibody (1:300) was then applied for 1 h at 378C in the dark. Following each step, the samples were analysed under a dual fluorescence microscope (LSM 510 META; Carl Zeiss).
Statistical analyses
Numerical data are presented as means + SEM. Comparisons between groups were performed using a two-tailed Student's t-test or one-way ANOVA test for multiple comparisons. The threshold of significance was set at P , 0.05.
Results
bL reduces BP in SHR and increases the NAD 1 /NADH ratio in endothelial cells
As a result of bL supplementation in SHR, SBP and DBP were significantly reduced in both bL (159 + 3 mmHg) and bL + L-NAME (154 + 3 mmHg) groups ( Figure 1B and C ) when compared with the control (179 + 3 mmHg) at 3 weeks post-treatment. However, following an additional week of L-NAME treatment, the BP-lowering effect of bL in the bL + L-NAME group was blocked, and the SBP rebounded to a level beyond that of the control group (212 + 8 mmHg). The rebound-elevated BP in the bL + L-NAME group was reversed by the cessation of L-NAME administration for 1 week. These results were reproduced with a second treatment of L-NAME to the same group. In contrast, the lowered SBP level was maintained in the bL group ( Figure 1B and C ) . These studies strongly support the model that bL decreases BP in a hypertensive animal model in an endothelium-dependent manner. Accordingly, we have used bEnd.3 cells to investigate whether bL increases the cellular NAD + /NADH ratio via NQO1 activation in endothelial cells. The total cellular NAD + /NADH ratio in mouse bEnd.3 cells was significantly increased by bL treatment ( Figure 1D ). The pyruvate/lactate ratio representing the cytosolic free NAD + /NADH ratio 28 was also significantly increased by bL treatment ( Figure 1E ).
bL improves vasomotor function in SHR
An ex vivo organ-bath study was performed to measure the effect of bL on aortic tension in SHR treated with bL for 4 weeks. Acetylcholine-induced (endothelium-dependent) vasorelaxation was improved in rings from bL-treated SHR (Figure 2A) . In contrast, endothelium-independent vasodilation induced by the NO donor sodium nitroprusside was comparable between rings from control and bL-treated SHR ( Figure 2B) . Similarly, acetylcholine-induced vasodilation was absent in both control and bL-treated rings treated with L-NAME ( Figure 2A) . bL treatment, therefore, is believed to promote endothelium-dependent vasodilation and vascular bioavailability of NO through an eNOS-dependent mechanism.
3.3 bL stimulates eNOS activity through serine phosphorylation
Next, we used HAEC and bEnd.3 cells to investigate whether bL induces phosphorylation of eNOS at Ser 1177 , a catalytically active phosphorylation site. As shown in Figure 3A , B, C, and D, bL stimulated eNOS-Ser 1177 phosphorylation in a concentration-and time- On the basis of these results, we suggest that bL promotes eNOS activity by regulating Ser 1177 phosphorylation.
bL-induced eNOS activation is dependent on PI3K/Akt and AMPK pathways
Ser 1177 phosphorylation and subsequent eNOS activation in response to several distinct eNOS activators is mediated by PI3K/Akt or AMPK activation. 11 -13 Therefore, we investigated whether bL activates Akt or AMPK, and whether the activation precedes eNOS-Ser 1177 phosphorylation in vitro. Phosphorylation of both Akt and AMPK was detected within 5 min (HAEC) or 1 min (bEnd. 3 cells) of bL treatment. This is consistent with either, or both, signalling pathways being involved in eNOS activation ( Figure 4A and B) . To identify the kinase involved in eNOS-Ser 1177 phosphorylation, bEnd.3 cells were treated with inhibitors of PI3K (LY249002) and AMPK (compound C) prior to bL treatment. Figure 4C shows that compound C had no effect on bL-induced eNOS phosphorylation. However, LY249002 dramatically inhibited the effect of bL on eNOS phosphorylation. These data indicate that bL-induced eNOS-Ser 1177 phosphorylation is mediated through Akt signalling but not by AMPK.
To further explore our hypothesis that the AMPK pathway is not required for bL-induced eNOS phosphorylation, we used a dominantnegative AMPK (Ad-dnAMPKa) expressing adenovirus to inhibit AMPK in bEnd.3 cells. Figure 4D shows that AMPK activation by AICAR did not increase eNOS phosphorylation in bEnd.3 cells. Interestingly, in cells overexpressing Ad-dnAMPKa, bL seemed to diminish eNOS phosphorylation. This was due to decreased eNOS protein levels resulting from AMPKa inhibition, an observation consistent with a previous study. 13 Moreover, inhibition of endogenous AMPK by Ad-dnAMPKa transfection resulted in a time-dependent decrease in eNOS protein levels followed by a dnAMPKa increase ( Figure 4E ). These studies demonstrate that AMPK is also involved in bL-stimulated eNOS activation in endothelial cells through regulation of eNOS protein expression.
bL-stimulated phosphorylation of eNOS/Akt/AMPK is mediated by a NQO1-dependent increase in intracellular calcium
To investigate whether the bL-induced increase in the cellular NAD + / NADH ratio ( Figure 1D and E Figure 5A ). The effect of bL on [Ca 2+ ]i was also suppressed using a RyR antagonist (8-Br-cADPR) and NQO1 inhibitors (dicoumarol and ES936) ( Figure 5A and B) . We next identified the molecular mechanisms underlying bL-induced intracellular calcium flux in endothelial cells. Hypotensive effect of NQO1 activation Pre-treatment with BABTA-AM completely abolished bL-stimulated eNOS/Akt/AMPK phosphorylation. EGTA also partially inhibited phosphorylation of eNOS and Akt by bL ( Figure 5C ). RyR blockade with ADP-ribosyl cyclase inhibitor (nicotinamide) and 8-Br-cADPR also inhibited eNOS/Akt/AMPK phosphorylation by bL ( Figure 5D ). bL-induced phosphorylation of eNOS, Akt, and AMPK were all decreased by NQO1 inhibition, achieved by Nqo1 siRNA transfection or ES936 treatment ( Figure 5E ). Intriguingly, pre-treatment with KN-93, a specific inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII), resulted in complete blockage of eNOS and Akt phosphorylation by bL ( Figure 5F ). These data strongly suggest that bL-induced increases in [Ca 2+ ]i occur prior to eNOS activation resulting from Akt and AMPK phosphorylation in endothelial cells.
bL treatment increases aortic eNOS activity in SHR
We sought to confirm the aforementioned bEnd.3 in vitro data with an in vivo study of aortic eNOS activation in bL-treated SHR. eNOS and Akt phosphorylation increased after 3 days and 4 weeks of bL treatment. However, Akt phosphorylation then decreased within 6 weeks of bL treatment, corresponding with a reduction in eNOS phosphorylation ( Figure 6A ). Total eNOS protein levels were dramatically increased at all measured time points following bL treatment in SHR aorta. This was associated with increased AMPK phosphorylation ( Figure 6A) . The bL-induced increase in eNOS expression in the aorta was confirmed histologically. Intense eNOS staining localized to the aortic endothelium was observed after 6 weeks of bL treatment ( Figure 6B ). These data indicate that eNOS phosphorylation and protein expression are all stimulated by bL treatment, resulting in increased eNOS activity in the aorta and reduced SHR BP.
Discussion
In this study, we found that bL treatment increased cytoplasmic NAD + /NADH ratio through NQO1 activation resulting in reduced BP and vascular tension in SHR. These effects were completely blocked by eNOS inhibition with L-NAME (Figures 1 and 2 ). This data strongly suggested that the hypotensive effect of bL resulted from endothelial eNOS activity modulation. As we were interested in endothelial cell eNOS modulation by bL, we measured cellular NAD + /NADH ratio in endothelial cells. As expected, bL treatment significantly increased total NAD + /NADH ratio ( Figure 1D ) and the cytoplasmic pyruvate/lactate ratio indicating free NAD + /NADH ratio 28 ( Figure 1E ) in endothelial cells, and these results were considered a consequence of bL-induced NQO1 activation. Additionally, eNOS phosphorylation was also relatively decreased in 6 weeks bL-treated SHR, which have showed reduced BP ( Figure 6A ). From these results, it was assumed that bL-induced increase in cellular NAD + /NADH ratio ameliorated hypertension through vascular tone control via eNOS modulation under hypertensive stress conditions. In current study, meanwhile, eNOS is a downstream protein of NQO1, and L-NAME is a specific inhibitor of eNOS. Because we thought that L-NAME might not affect the cellular NAD + /NADH ratio regulated by NQO1, bL, and L-NAME co-treated group was excluded in cellular NAD + /NADH ratio analysis in vitro.
In general, vascular endothelial cells are ubiquitous, multifunctional, and play a crucial role in regulating BP through the control of vascular tone and homoeostasis. 6, 31 BP is mediated by changes in the generation and release of the vasodilator NO. This occurs in response to various stimuli. eNOS-Ser 1177 phosphorylation through the PI3K-dependent Akt and maintenance of eNOS protein expression by AMPK are indispensable for eNOS activation. 11 -13 In the present study, bL was shown to activate eNOS-Ser 1177 phosphorylation along with the active phosphorylation of Akt ( Figures 3, 4 , and 6). The AMPK inhibitor compound C did not block this phenomenon. However, LY249002 and Wortmannin (PI3K inhibitors) inhibited this eNOS phosphorylation ( Figures 4C and 5F ). Furthermore, bL increased eNOS protein levels through AMPK phosphorylation in all measured time points in bL-treated SHR aortic tissues ( Figure 6 ). The eNOS protein levels were decreased by AMPK inhibition with dnAMPKa in bEnd.3 cells (Figure 4D and E). Based on these results, it is assumed that the hypotensive effect of bL is due to the synergic effect of AMPK on eNOS protein expression and PI3K/Akt on eNOS phosphorylation. Next, we explored the upstream mediator of eNOS phosphorylation following bL-activation of NQO1 in bEnd. 3 reported to increase cytosolic Ca 2+ levels and activate AMPK by the calcium/calmodulin-dependent protein kinase kinase-b (CaMKKb).
34
PI3K is positively regulated by Ca 2+ via CaMKII. 35 Our results show that increased PI3K/Akt-eNOS phosphorylation by bL was completely abolished by CaMKII inhibition in this study ( Figure 5F ). Taken together with previous studies, 34, 35 our results provide strong evidence suggesting that bL-induced phosphorylation of PI3K/Akt and AMPK is mediated by Ca 2+ -induced activation of CaMKII or CaMKKb.
In conclusion, this is the first study demonstrating that NQO1 activation by bL leads to decreased BP in a hypertensive animal model. As summarized in Figure 6C , the hypotensive effect of bL is attributable to NO-mediated vascular relaxation via aortic eNOS activation. This is mediated by active phosphorylation of PI3K/Akt and AMPK through [Ca 2+ ]i elevation, which is mediated by modulation of cytoplasmic NAD + /NADH ratio via NQO1 activation. Previous studies reported that calorie restriction and exercise have beneficial effects on BP in hypertensive patients during clinical trials. 36, 37 In addition, calorie restriction and exercise were reported to lead to an increase in NAD + /NADH ratio. 38 -40 Therefore, modulation of cellular NAD + / NADH ratio might be a new therapeutic approach for hypertension.
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